Lpath, an industry leader in bioactive lipid-targeted therapeutics, has been invited to present data from its Lpathomab program in models of central nervous system injury, including traumatic brain injury (TBI), at Arrowhead’s 3rd Annual Traumatic Brain Injury Conference.
Lpathomab is a first-in-class monoclonal antibody that binds to and neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has been implicated in neuropathic pain, neurotrauma, and various other disorders.
Lpath’s vice president and founder, Roger Sabbadini, will present at the Sheraton Crystal City Hotel in Washington, DC on March 7, 2013, at 11:15 a.m. He will discuss a study entitled, “Monoclonal Anti-lysophosphatidic Acid Antibodies Are Neuroprotective after Experimental TBI.” The study is part of a collaboration between Lpath and scientists at the University of Melbourne (Dr Alice Pebay and Dr Peter Crack), UCLA Brain Injury Research Center (Dr Neil Harris), and University of Kentucky (Dr Andrew Morris).
- Click here to visit the Lpath website
- Click here to visit the University of Melbourne website page for researcher Dr Alice Pebay
- Click here to visit the University of Melbourne website page for researcher Dr Peter Crack
- Click here to visit the UCLA Brain Injury Research Centre website page for researcher Dr Neil Harris
- Click here to visit the University of Kentucky website page for Dr Andrew Morris
